Drug Discovery
ByIs AI Poised to Replace the Traditional Drug Discovery Lab? Nvidia CEO Signals a Paradigm Shift in Pharma R&D
23 January 2026 Executive Summary Nvidia CEO Jensen Huang has underscored the transformative potential of artificial intelligence in…
Is Short-Term Cost Control Undermining Long-Term Innovation? Novartis Calls for Structural Reform in Global Healthcare
23 January 2026 Executive Summary Novartis has issued a call for structural reform in global healthcare policy, warning…
Is Regional Distribution Becoming a Strategic Lever for Big Pharma? Novartis Expands European Reach Through Malta Partnership
23 January 2026 Executive Summary Novartis Pharma Services AG has entered into a strategic distribution agreement with Vivian…
Can Localized Manufacturing Shield Big Pharma from Trade Volatility? Novartis Targets Zero U.S. Tariff Exposure by Mid-2026
23 January 2026 Executive Summary Novartis CEO Vas Narasimhan has outlined a decisive trade-risk mitigation strategy, stating that…
Can Amgen’s Strategic Partnerships Redefine Access and Growth in the GLP‑1 Market?
23 January 2026 Executive Summary Amgen is actively exploring strategic collaborations with telehealth platforms and other access-focused partners…
Could Amgen’s 340B Pricing Practices Face Legal and Market Scrutiny?
23 January 2026 Executive Summary A healthcare advocacy group, Sagebrush, has filed a lawsuit against Amgen Inc., alleging…
